<SEC-DOCUMENT>0001193125-18-292844.txt : 20181004
<SEC-HEADER>0001193125-18-292844.hdr.sgml : 20181004
<ACCEPTANCE-DATETIME>20181004091635
ACCESSION NUMBER:		0001193125-18-292844
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20181004
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181004
DATE AS OF CHANGE:		20181004

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARROWHEAD PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000879407
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				460408024
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38042
		FILM NUMBER:		181107010

	BUSINESS ADDRESS:	
		STREET 1:		225 SOUTH LAKE AVENUE
		STREET 2:		SUITE 1050
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91101
		BUSINESS PHONE:		626-304-3400

	MAIL ADDRESS:	
		STREET 1:		225 SOUTH LAKE AVENUE
		STREET 2:		SUITE 1050
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91101

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARROWHEAD RESEARCH CORP
		DATE OF NAME CHANGE:	20040112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE GROUP INC
		DATE OF NAME CHANGE:	20020509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE INC
		DATE OF NAME CHANGE:	19940224
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d633224d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO SECTION 13 OR 15(D) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): October&nbsp;4, 2018 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Arrowhead Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-38042</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">46-0408024</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>225 South Lake Avenue, Suite 1050, Pasadena, CA 91101 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code <FONT STYLE="white-space:nowrap">(626)&nbsp;304-3400</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act
(17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4</FONT> (c) under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c)</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&nbsp;405 of the Securities Act of 1933
(&#167;230.405 of this chapter) or <FONT STYLE="white-space:nowrap">Rule&nbsp;12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Emerging growth company&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a)&nbsp;of the Exchange Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;1.01 Entry into a Material Definitive Agreement. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>License and Research Collaboration Agreements and Common Stock Purchase Agreement </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On October&nbsp;4, 2018, Arrowhead Pharmaceuticals, Inc., a Delaware corporation (the &#147;Company&#148;), entered into a License Agreement
(the &#147;License Agreement&#148;) and a Research Collaboration and Option Agreement (the &#147;Collaboration Agreement&#148;) with Janssen Pharmaceuticals, Inc., a Pennsylvania corporation (&#147;Janssen&#148;), part of the Janssen Pharmaceutical
Companies of Johnson&nbsp;&amp; Johnson. Also on October 4, 2018, the Company entered into a Common Stock Purchase Agreement (the &#147;Stock Purchase Agreement&#148;) and Registration Rights Agreement (the &#147;Registration Rights Agreement&#148;)
with Johnson&nbsp;&amp; Johnson Innovation-JJDC, Inc. (&#147;JJDC&#148;), a New Jersey corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the License Agreement, Janssen
will receive a worldwide, exclusive license to the Company&#146;s <FONT STYLE="white-space:nowrap">ARO-HBV</FONT> program, the Company&#146;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potentially
curative therapy for patients with chronic hepatitis B virus infection. Beyond the Company&#146;s ongoing Phase 1 / 2 study of <FONT STYLE="white-space:nowrap">ARO-HBV</FONT> (which will remain the responsibility of the Company), Janssen will be
wholly responsible for clinical development and commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the Collaboration Agreement, Janssen will be able to select up
to three new targets against which Arrowhead will develop clinical candidates. These candidates are subject to certain restrictions and will not include candidates in the Company&#146;s current pipeline. The Company will perform discovery,
optimization and preclinical development on selected targets, entirely funded by Janssen, sufficient to allow the filing of a U.S. Investigational New Drug application or equivalent, at which time Janssen will have the option to take an exclusive
license to the Company&#146;s intellectual property rights covering that compound. If the option is exercised, Janssen will be wholly responsible for clinical development and commercialization of each optioned compound. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the Stock Purchase Agreement, the Company will sell 3,260,869 shares of common stock (the &#147;Shares&#148;) to JJDC at a price of
$23.00 per share. The Shares are being sold in a private placement that is exempt from registration under Section&nbsp;4(a)(2) of the Securities Act of 1933, as amended (the &#147;Act&#148;). Pursuant to the Registration Rights Agreement, the
Company will be obligated to register the Shares under the Act for resale by JJDC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the terms of the agreements taken together, the
Company will receive (i)&nbsp;$175&nbsp;million as an upfront payment, (ii)&nbsp;$75&nbsp;million in the form of an equity investment by JJDC in Arrowhead common stock pursuant to the Stock Purchase Agreement, (iii)&nbsp;up to $1.6&nbsp;billion in
development, regulatory and sales milestones payments for the License Agreement, and (iv)&nbsp;up to $1.9&nbsp;billion in development, regulatory and sales milestone payments for the three additional targets covered under the Collaboration
Agreement. The Company is further eligible to receive tiered royalties up to the <FONT STYLE="white-space:nowrap">mid-teens</FONT> on product sales for products commercialized under the License Agreement and the Collaboration Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The transactions contemplated under the License Agreement, Collaboration Agreement and Stock Purchase Agreement are subject to customary
closing conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. Closing is expected to occur in the fourth calendar quarter of 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;3.02 Unregistered Sales of Equity Securities. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The disclosure set forth above under Item 1.01 regarding the offer and sale of the Shares is incorporated herein by reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;7.01 Regulation FD Disclosure. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Attached hereto as Exhibit 99.2 are prepared remarks of the Company, which were presented on a conference call today, October&nbsp;4, 2018 by
Company management to investors, analysts and others. The prepared remarks will be posted on the Company&#146;s website, www.arrowheadpharma.com. The information included in Exhibit&nbsp;99.2 shall not be deemed &#147;filed&#148; for purposes of
Section&nbsp;18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)
Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;No.&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d633224dex991.htm">Press Release, dated October&nbsp;4, 2018</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d633224dex992.htm">Prepared Conference Call Remarks, dated October&nbsp;4, 2018</A></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: October&nbsp;4, 2018 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ARROWHEAD PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Kenneth Myszkowski</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Kenneth Myszkowski</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d633224dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g633224g32l22.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PRESS RELEASE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Oct.
4, 2018 </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Arrowhead Enters $3.7 Billion License and Collaboration Agreements with Janssen </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#150; Upon closing, Arrowhead to receive $250&nbsp;million, consisting of $175&nbsp;million upfront payment from Janssen and $75&nbsp;million
equity investment from Johnson&nbsp;&amp; Johnson Innovation &#150; JJDC, Inc. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#150; Arrowhead eligible to receive additional
$3.5&nbsp;billion in potential milestone payments, and potential further royalties on commercial sales </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#150; Janssen to receive a
worldwide exclusive license for <FONT STYLE="white-space:nowrap">ARO-HBV</FONT> and an option to collaborate on up to three new targets </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#150; Arrowhead will hold a conference call and webcast today, Oct. 4, at 8:30 a.m. ET </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>PASADENA, Calif., Oct. 4, 2018</B> &#150; Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it entered into a license and
collaboration agreement with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson&nbsp;&amp; Johnson, to develop and commercialize <FONT STYLE="white-space:nowrap">ARO-HBV.</FONT> In addition, Arrowhead entered into
a research collaboration and option agreement with Janssen to potentially collaborate for up to three additional RNA interference (RNAi) therapeutics against new targets to be selected by Janssen. The transactions have a combined potential value of
over $3.7&nbsp;billion for Arrowhead. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the terms of the agreement, Arrowhead will receive $175&nbsp;million as an upfront payment.
Separately, Johnson&nbsp;&amp; Johnson Innovation &#150; JJDC, Inc. (JJDC) will make a $75&nbsp;million equity investment in Arrowhead at a price of $23.00 per share of Arrowhead common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Arrowhead is eligible to receive up to approximately $1.6&nbsp;billion in milestone payments for the HBV license agreement, including a
$50&nbsp;million milestone payment linked to a Phase&nbsp;2 study. Arrowhead is also eligible to receive approximately $1.9&nbsp;billion in option and milestone payments for the collaboration agreement related to up to three additional targets.
Arrowhead is further eligible to receive tiered royalties up to mid teens on product sales. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;This agreement represents an important next step for
<FONT STYLE="white-space:nowrap">ARO-HBV.</FONT> Arrowhead has established a leadership position in the field over the past several years, and Janssen&#146;s proven development capabilities, global commercial reach, and commitment to HBV make it the
ideal partner to potentially accelerate our goal of bringing a functional cure to patients with chronic HBV,&#148; said Christopher Anzalone, Ph.D., Arrowhead&#146;s president and CEO. &#147;The collaboration also represents further validation of
the TRiM<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> platform and provides an important opportunity to create up to three additional novel medicines by leveraging Arrowhead&#146;s speed and expertise in RNAi drug discovery and
Janssen&#146;s clinical development and commercial capabilities.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the agreement, Janssen receives a worldwide exclusive
license to the <FONT STYLE="white-space:nowrap">ARO-HBV</FONT> program, Arrowhead&#146;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potentially curative therapy for patients with chronic
hepatitis&nbsp;B virus infection. Beyond AROHBV1001, Arrowhead&#146;s ongoing Phase&nbsp;1/2 study of <FONT STYLE="white-space:nowrap">ARO-HBV,</FONT> Janssen will be wholly responsible for clinical development and commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Janssen can also select up to three new targets, against which Arrowhead will develop clinical candidates. These potential new candidates will
leverage Arrowhead&#146;s proprietary TRiM&#153; platform, and do not include Arrowhead&#146;s current pipeline. Arrowhead will perform discovery, optimization, and preclinical development, entirely funded by Janssen, sufficient to allow the filing
of a U.S. Investigational New Drug application or equivalent, at which time Janssen will have the option to take an exclusive license. If the option is exercised, Janssen will be wholly responsible for clinical development and commercialization.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The closing of the transactions is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and
is expected to close during the fourth quarter of 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference Call and Webcast Details </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Investors may access a live audio webcast on the Company&#146;s website at <U>http://ir.arrowheadpharma.com/events.cfm</U>. For analysts that
wish to participate in the conference call, please dial <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">855-215-6159</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">315-625-6887</FONT></FONT> and
provide Conference ID 2649806. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A replay of the webcast will be available on the company&#146;s website approximately two hours after the
conclusion of the call and will remain available for 90&nbsp;days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3&nbsp;days. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To access the audio replay, dial <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">855-859-2056</FONT></FONT> or <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">404-537-3406</FONT></FONT> and provide Conference ID 2649806. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About AROHBV1001 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">AROHBV1001 (<U>NCT03365947</U>) is evaluating the safety, tolerability, and pharmacokinetic effects of single-ascending doses (SAD) of <FONT
STYLE="white-space:nowrap">ARO-HBV</FONT> in healthy adult volunteers, as well as the safety, tolerability, and pharmacodynamic effects of multiple-ascending doses (MAD) of <FONT STYLE="white-space:nowrap">ARO-HBV</FONT> in patients with chronic
HBV. Dosing in the SAD portion of the study is complete and included five cohorts at dose levels of 35, 100, 200, 300, and 400 mg. Dosing in the MAD portion of the study is ongoing and includes cohorts receiving three doses of <FONT
STYLE="white-space:nowrap">ARO-HBV</FONT> either weekly, <FONT STYLE="white-space:nowrap">bi-weekly,</FONT> or monthly. Arrowhead submitted a late-breaking abstract with clinical data to the <U>Liver Meeting<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP></U>, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD), being held in November 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Arrowhead Pharmaceuticals </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of
RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits
the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead&#146;s RNAi-based therapeutics leverage this natural pathway of gene silencing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company&#146;s email
list and receive news directly, please visit <U>http://ir.arrowheadpharma.com/email-alerts</U>. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safe Harbor Statement under the Private Securities Litigation Reform Act: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>This news release contains forward-looking statements within the meaning of the &#147;safe harbor&#148; provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result
of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the future success of our scientific
studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report
on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> and subsequent Quarterly Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> discuss some of the important risk factors that may affect our business, results of operations and
financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts:
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Arrowhead Pharmaceuticals, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vince
Anzalone, CFA </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">626-304-3400</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>ir@arrowheadpharma.com </U></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investors and Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LifeSci Advisors, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brian Ritchie </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">212-915-2578</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>britchie@lifesciadvisors.com </U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>www.lifesciadvisors.com
</U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Source: </B>Arrowhead Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># # # </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d633224dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 99.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARROWHEAD PHARMACEUTICALS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Arrowhead/Janssen
Collaboration Conference Call &#150; Prepared Remarks </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>October&nbsp;4, 2018 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5:30 AM Pacific time </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operator </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Ladies and gentlemen welcome to the Arrowhead Pharmaceuticals conference call. Throughout today&#146;s recorded presentation all participants
will be in a listen-only mode. After the presentation, there will be an opportunity to ask questions. I will now hand the conference call over to Vincent Anzalone, Vice President of Investor Relations for Arrowhead. Please go ahead Vince. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vince Anzalone </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Good morning everyone. We
are happy to announce today that Arrowhead and Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson and Johnson, have signed a license agreement whereby Janssen gets an exclusive worldwide license to
Arrowhead&#146;s <FONT STYLE="white-space:nowrap">ARO-HBV</FONT> program and also a collaboration agreement for up to three new candidates utilizing our proprietary Targeted RNAi Molecule, or
TRiM<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, platform against targets to be selected by Janssen. Our president and CEO, Dr.&nbsp;Christopher Anzalone, will provide an overview of the deal and give some color about what it means for
Arrowhead, and we will then open up the call to your questions. Also with us today for the Q&amp;A portion of the call are Ken Myszkowski, our chief financial officer, and Patrick O&#146;Brien, our general counsel. Dr.&nbsp;Bruce Given, our COO and
head of R&amp;D is away today. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Before we begin, I would like to remind you that comments made during today&#146;s call
contain certain forward-looking statements within the meaning of Section&nbsp;27(A) of the Securities Act of 1933 and Section&nbsp;21(E) of the Securities Exchange Act of 1934. All statements other than statements of historical fact, including
without limitation those with respect to Arrowhead&#146;s goals, plans, and strategies are forward-looking statements. These include statements regarding our expectations around the development, safety and efficacy of our drug candidates, projected
cash runway, and expected future development activities by Arrowhead or our partners. These statements represent management&#146;s current expectations and are inherently uncertain. Thus, actual results may differ materially. Arrowhead disclaims any
intent and undertakes no duty to update any of the forward-looking statements discussed on today&#146;s call. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You should refer to the
discussions under risk factors in Arrowhead&#146;s annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and the Company&#146;s subsequent quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for additional matters to
be considered in this regard, including risks and other considerations that could cause actual results to vary from the presently expected results expressed in today&#146;s call. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">With that said, I&#146;d like to turn the call over to Christopher Anzalone, President and CEO of the Company. Chris? </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Chris Anzalone </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Thanks Vince. Good morning everyone and thank you for joining us today. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This morning we reported that Arrowhead and Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceuticals Companies of Johnson&nbsp;&amp;
Johnson, signed a license agreement for <FONT STYLE="white-space:nowrap">ARO-HBV</FONT> and a collaboration agreement for up to three RNAi therapeutic candidates that use our proprietary TRiM<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>
platform against new targets to be selected by Janssen. The total potential deal value is approximately $3.7&nbsp;billion plus royalties on commercial sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the terms of the HBV license agreement, Arrowhead will receive $175&nbsp;million as an upfront payment. In addition, Arrowhead will
receive $75&nbsp;million in the form of an equity investment by Johnson&nbsp;&amp; Johnson Innovation &#150; JJDC, Inc., at a price of $23.00 per share of Arrowhead common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Arrowhead is eligible to receive up to approximately $1.6&nbsp;billion in milestone payments for the HBV license agreement, including a
$50&nbsp;million near-term milestone payment after initiation of a Phase 2 study. Arrowhead is also eligible to receive approximately $1.9&nbsp;billion in option and milestone payments for the collaboration agreement related to up to three
additional targets. Arrowhead is further eligible to receive tiered royalties up to mid teens on product sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Janssen will receive a
worldwide exclusive license to the <FONT STYLE="white-space:nowrap">ARO-HBV</FONT> program, Arrowhead&#146;s third-generation subcutaneously administered RNAi therapeutic candidate that leverages the TRiM&#153; platform and is being developed as a
potentially curative therapy for patients with chronic hepatitis B infection. Arrowhead will be responsible for running AROHBV1001, our ongoing Phase 1/2 study of <FONT STYLE="white-space:nowrap">ARO-HBV,</FONT> and Janssen will be wholly
responsible for funding and conducting all future clinical development and commercialization activities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Janssen may select up to three new targets, against which Arrowhead will develop clinical
candidates. These potential new candidates will leverage Arrowhead&#146;s proprietary TRiM&#153; platform, and do not include targets in Arrowhead&#146;s current pipeline. Arrowhead will perform discovery, optimization, and preclinical development,
entirely funded by Janssen, sufficient to allow the filing of a U.S. IND or equivalent, at which time Janssen will have the option to take an exclusive license. If the option is exercised, Janssen will be wholly responsible for funding and
conducting all clinical development and commercialization activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Let&#146;s unpack what this agreement means strategically, and
begin with what it means for patients with chronic HBV infection. I believe this partnership maximizes the chances that patients could have access to functional cures, and this is a big thing. I view <FONT STYLE="white-space:nowrap">ARO-HBV</FONT>
as a very exciting experimental agent against chronic HBV infection and we recently presented early data demonstrating that we may be silencing the virus deeper than has ever been reported in hard to treat patient populations such as HBeAg negatives
that are increasingly predominating in many regions. We are doing this with a drug candidate that has been well tolerated thus far and with a platform that has also shown impressive activity and tolerability in a different therapeutic environment, <FONT
STYLE="white-space:nowrap">alpha-1</FONT> antitrypsin deficiency. AASLD has accepted our late breaker submissions on both of these programs and we look forward to presenting data in November. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our innovation and execution have been unmatched: we went from a standing start to the current clinical evidence of activity involving more
than 100 human subjects across both programs in well less than two years. While we have not yet seen functional cures after just 3 doses of <FONT STYLE="white-space:nowrap">ARO-HBV,</FONT> we believe that we have created something that can be a
powerful tool against chronic HBV infection in the near- to <FONT STYLE="white-space:nowrap">mid-term.</FONT> So the table is set. Much still needs to be done, but we have put <FONT STYLE="white-space:nowrap">ARO-HBV</FONT> in a position where
success against this disease is possible. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Why, then, should we enter into this partnership now? Why not continue the leadership
position we have created for ourselves and push deeper in the clinic toward the market? Sometimes leadership is about knowing where you can lead and when you should be part of a team. For this disease at this time in Arrowhead&#146;s development,
Janssen is simply better positioned to continue our forward progress and push <FONT STYLE="white-space:nowrap">ARO-HBV</FONT> to market. I believe that Arrowhead did what no other company could have done to get to where we are, and now I think that
Janssen is the ideal company to take the baton. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Let&#146;s take a closer look at that. The right Phase 2b studies will be large,
expensive, and complicated. Combinations with different compound classes should be interrogated and the permutations are extensive because many different dosing schedules for each compound are possible. Further, it is unclear how long treatment
would have to be provided in order to possibly induce consistent functional cures, so there is potentially substantial expense and a large clinical team with experience in global infectious disease studies will be required. These would be challenges
for Arrowhead at this time, and Janssen has expansive resources and a demonstrated commitment to these types of programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As important as
this next step is, it represents just the beginning of the value of this partnership for Arrowhead. Should the Phase 2b studies succeed, large pivotal studies would follow, and, ultimately, a global commercial launch. The industry&#146;s experience
with Hepatitis C is telling: speed, experience in large complex clinical studies, and established commercial infrastructure will be critical for success. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Janssen has these capabilities, while Arrowhead is not tooled for this, at least not yet and
not for this disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">So it clearly makes sense to partner <FONT STYLE="white-space:nowrap">ARO-HBV</FONT> with Janssen at this time from
a strategic standpoint, and the economics, guaranteed and contingent, make this deal transformational for us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Let&#146;s take a closer
look at the economics of the deal. As I mentioned, we will receive $250&nbsp;million upfront between the equity investment and cash payment. We are eligible to receive a $50&nbsp;million milestone payment linked to the Phase 2b study, giving us a
total of potentially $300&nbsp;million in the near term. Importantly, our HBV cost exposure will stop, saving us at least <FONT STYLE="white-space:nowrap">$25-30&nbsp;million</FONT> in 2019 alone, so this is a possible infusion of over
$325&nbsp;million in the near term on top of the nearly $90&nbsp;million in combined cash that we reported in our last <FONT STYLE="white-space:nowrap">10-Q</FONT> and the recently triggered milestone payment from Amgen that we announced in August.
This keeps us from needing to access the capital markets any time soon. Add to this the remaining $600&nbsp;million in potential milestone payments from the current Amgen agreement and the remaining $3.4&nbsp;billion in potential milestone payments
from Janssen and we have potential access to an additional $4&nbsp;billion plus royalties in the years ahead. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This is a deep well indeed,
and it enables us to create substantial value by retaining our pipeline. Do we need to partner our programs against AAT, APOC3, ANGPTL3, Hif <FONT STYLE="white-space:nowrap">2-alpha,</FONT> ENaC and more? Potentially not: we now have substantially
more flexibility to capture more value from these and future programs. For a small biotech company to make the leap to a large, vertically integrated pharmaceutical company it needs good technology, good drug candidates, a strong balance sheet, and
access to growth capital. We now have all of these, and this is where we are headed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While we certainly may tap the capital markets in the future to help fund large capital
expenditures or endeavors such as building a commercial organization, we believe that we may no longer be dependent on them to fund operations. As I mentioned, this deal is transformational for Arrowhead. We now have a strong partner for HBV to
maximize our chances of bringing <FONT STYLE="white-space:nowrap">ARO-HBV</FONT> to a broad market <B><I>and </I></B>we have the capital necessary to control development and commercialize our pipeline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This is important from a value capture standpoint and a risk tolerance standpoint. HBV, for all its potential economic and public health
upside, continues to have target and reimbursement risk associated with it. These risks are better navigated by a larger company that has existing infectious disease expertise. We think the rest of our pipeline is largely based on well validated
targets, understandable regulatory pathways, and clear commercial opportunities. Swapping control of <FONT STYLE="white-space:nowrap">ARO-HBV</FONT> for the financial resources to develop and commercialize all or a large portion of our growing
pipeline is a good trade for us. The TRiM<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> platform is enormously flexible, and we have numerous opportunities to develop innovative new medicines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The current deal with Janssen also speaks to extracting additional value from the TRiM<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>
platform. Janssen will have an option to develop and commercialize 3 additional targets. We view this as further validation of the platform as well as new value creation. The additional targets will be outside of Arrowhead&#146;s current pipeline so
will be truly novel for us and, therefore, represent found value. Janssen would fully fund and control clinical development and, ultimately, commercialization. As such, Arrowhead would have a strong partner with global reach to take these potential
new medicines to market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Before we take questions, I want to remind everybody that we announced on September 24<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> that we will be hosting an Analyst R&amp;D Day in New York on October 16. During this event, Arrowhead management and noted lipidologist, Dr.&nbsp;Ira Goldberg, Chief of the Division of
Endocrinology, Diabetes and Metabolism at New York University Langone School of Medicine, will discuss what&#146;s next in Arrowhead&#146;s emerging lipid pipeline. Specifically, our most advanced candidates:
<FONT STYLE="white-space:nowrap">ARO-APOC3</FONT> for patients with hypertriglyceridemia; and, <FONT STYLE="white-space:nowrap">ARO-ANG3</FONT> for patients with dyslipidemia; both of which are on track for CTA filings by the end of 2018. We will
also be discussing our first two programs targeting extra-hepatic tissues. These are <FONT STYLE="white-space:nowrap">ARO-ENaC</FONT> for patients with cystic fibrosis, and <FONT STYLE="white-space:nowrap">ARO-HIF2</FONT> for patients with clear
cell renal cell carcinoma. Both of these extra-hepatic candidates have CTAs planned for 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are extremely excited about what&#146;s
next and hope that you can listen to the webcast or can join us in person. We have accomplished a lot in recent years, but we feel that we are in the very early stages of explosive growth as a company, and the Janssen partnership provides fuel for
that growth. Think of that fuel in three ways: capital; expertise; and opportunities. It provides the capital we need to develop a number of new medicines that we will commercialize ourselves; it provides an experienced partner capable of developing
and commercializing <FONT STYLE="white-space:nowrap">ARO-HBV</FONT> and potentially 3 additional new medicines; and it enables us to take advantage of new opportunities by further developing and expanding the TRiM<SUP
STYLE="font-size:85%; vertical-align:top">TM</SUP> platform and revolutionary new medicines built on it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">I would now like to open the
call to your questions. Operator? </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operator </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Operator opens the call to questions</B> &#133; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g633224g32l22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g633224g32l22.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MPS8L?^)IXPN[P\PV"?9X_P#>/+&GU%LBEX-TBSELI[V>%)I6GD4>8-P4!CP
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M_K?FZ?+CCUYH O:Y:2W^B7=K  994VKN.!FFQ(GLH&ATZ"WE W)&$8=1TYH
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K H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
